PostPartum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the
most commonly used uterotonic drug to prevent and treat PPH in North America. However
oxytocin has a very short duration of action, requiring a continuous infusion to achieve
sustained uterotonic activity. Moreover large doses are associated with adverse effects like
hypotension, nausea, vomiting, dysrhythmias and ST changes. The Society of Obstetricians and
Gynecologists of Canada (SOGC) has recommended a single dose of 100 mcg of carbetocin at
elective cesarean delivery to promote uterine contraction. In three studies recently
performed at Mount Sinai Hospital, the investigators have found no difference in uterine
contractility between the doses of 20- 120 mcg carbetocin and that the ED90 is 14.8 mcg. Thus
a larger trial comparing the minimum effective dose determined in the previous three trials
with the standard 100 mcg dose is necessary to confirm these findings.
Phase:
N/A
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital